Butterfly Network Stock Surges 72% on FDA Clearance for iPhone 15 Ultrasound
2d ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
butterfly-networkbfl
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Butterfly Network, Inc. (NYSE: BFLY) shares surged 72% in pre-market trading on June 18, 2026, following an announcement that the U.S. Food and Drug Administration granted 510(k) clearance for its iQ3 handheld ultrasound probe. The new device is designed for use with Apple's iPhone 15 series, representing a significant generational leap in connectivity and processing power. The regulatory clearance triggers the company's strategic pivot toward a software-as-a-service subscription model, a shift long anticipated by institutional investors analyzing the point-of-care ultrasound market. Trading volume exceeded 25 million shares in the first hour, more than ten times the 30-day average, indicating intense speculative and fundamental interest.
The FDA's clearance arrives as the broader medtech sector faces pressure from elevated interest rates, which have compressed valuations for capital-intensive hardware firms. The last comparable regulatory catalyst for Butterfly Network was the 2020 clearance of its iQ+ probe, which propelled shares over 150% in the subsequent quarter. The current macro backdrop includes a 10-year Treasury yield at 4.2% and the S&P 500 Health Care Equipment index down 5% year-to-date, making outsized single-stock moves rare. What changed is the confluence of a finalized regulatory pathway and the maturation of the iPhone 15's computational ecosystem, which enables advanced AI-powered image analysis previously confined to cart-based systems. The trigger was the removal of the final regulatory overhang that had delayed the company's transition plan.
The stock's 72% surge lifted Butterfly Network's share price from a close of $1.85 on June 17 to approximately $3.18 in pre-market activity on June 18. This increased the company's market capitalization by roughly $250 million in a single session. The iQ3 probe connects via a proprietary Lightning connector, offering a 40% improvement in image acquisition speed compared to the previous iQ+ model. Historical trading data shows the stock's average daily volume for the past month was 2.3 million shares, a figure dwarfed by today's activity. A comparison of key metrics illustrates the scale of the move:
| Metric | June 17 Close | June 18 Pre-Market | Change |
|---|---|---|---|
| Share Price | $1.85 | $3.18 | +72% |
| 30-Day Avg Vol | 2.3M | 25M+ | +987% |
| Market Cap | ~$345M | ~$595M | +$250M |
The rally stands in stark contrast to peers; shares of GE HealthCare have gained 3% year-to-date, while the iShares U.S. Medical Devices ETF has declined 2% over the same period.
The clearance directly benefits semiconductor suppliers providing specialized components for the iQ3's transducer array, with companies like Texas Instruments and Analog Devices seeing increased order visibility. Secondary beneficiaries include telehealth platform providers like Teladoc Health and Amwell, which can integrate higher-fidelity imaging into remote consultations. A clear loser is the traditional ultrasound cart market, where established players like Siemens Healthineers and Philips may face incremental pricing pressure in the portable segment. The primary counter-argument is execution risk; Butterfly Network must successfully migrate its existing user base to higher-margin subscriptions while fending off new competitors drawn to the now-validated form factor. Positioning data indicates short covering fueled the initial spike, with days to cover exceeding five, followed by fresh long accumulation from healthcare-focused growth funds rotating out of more saturated therapeutics names.
The next immediate catalyst is Butterfly Network's Q2 2026 earnings report, scheduled for July 31, which will provide the first official guidance for iQ3 shipments and SaaS conversion rates. Investors will monitor the company's cash burn rate, as the manufacturing ramp for the new probe requires working capital. A key technical level to watch is the stock's 200-day moving average, currently near $2.40, which may now act as support. If the company reports iQ3 subscription attach rates above 60% in its first full quarter, it could validate the software margin thesis. Conversely, any manufacturing delays or softer-than-expected uptake from the existing customer base would likely trigger volatility, given the elevated expectations now priced into the stock. The December 2026 expiration of a key patent covering the probe's single-crystal transducer technology also introduces a long-term competitive watchpoint.
The iQ3 is the first Butterfly probe designed exclusively for the iPhone 15 platform, utilizing its faster processor and advanced neural engine for real-time image enhancement and measurement automation. It employs a next-generation transducer that improves penetration depth for abdominal and obstetric applications. This hardware-software integration is central to the company's strategy of locking users into its proprietary Butterfly Cloud ecosystem for image storage and analysis, moving beyond one-time device sales.
The new model involves selling the iQ3 hardware at a lower upfront cost, or potentially bundling it with a mandatory multi-year software subscription. The subscription fee, projected between $100 and $150 monthly per user, grants access to cloud storage, AI-driven diagnostic assistance tools, and continuous software updates. This shift aims to transform revenue from volatile hardware sales into predictable recurring income, improving gross margins from approximately 50% toward a 70% target over the next three years.
No other company has publicly announced FDA 510(k) clearance for a dedicated, single-crystal ultrasound probe connecting directly to the iPhone 15 as of June 18, 2026. Several startups have prototypes, and larger firms like GE have iPhone-compatible devices using older connection standards. Butterfly's clearance for this specific, optimized platform gives it a first-mover advantage of at least 12-18 months, a critical window to establish its SaaS platform before competing products reach the market.
The FDA clearance validates Butterfly Network's high-risk bet on the iPhone 15 platform, enabling its crucial shift from hardware vendor to a recurring-revenue software company.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.